DGAP-News: Cytos invites for the Annual Shareholders' Meeting 2012
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): AGM/EGM
Cytos invites for the Annual Shareholders' Meeting 2012
29.03.2012 / 17:31
---------------------------------------------------------------------
Schlieren (Zurich), Switzerland, 29 March, 2012 - Cytos Biotechnology Ltd
('Cytos'), today announced that the Annual Shareholders' Meeting 2012 will
take place on Friday, April 20, 2012 at 3 p.m. at Cytos' offices in
Schlieren/Zurich (Switzerland).
In addition to the ordinary agenda items, the shareholders are also invited
to vote on the recapitalization as announced on March 21, 2012 and in
particular on the capital increase. The invitation as well as the agenda
items including detailed information about the recapitalization can be
found on the following website:
http://www.cytos.com/userfiles/file/AGM_2012.pdf
For further information please contact:
Cytos Biotechnology Ltd
Harry Welten
Chief Financial Officer
Tel.: +41 44 733 46 46
e-Mail: harry.welten(at)cytos.com
Website: www.cytos.com
About Cytos Biotechnology Ltd
Cytos Biotechnology Ltd is a Swiss public biotechnology company that
specializes in the development and commercialization of a new class of
biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM) are
intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce the desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Cytos' Immunodrug(TM) candidates are being developed both
in-house and together with Novartis, Pfizer and Pfizer Animal Health.
Founded in 1995 as a spinoff from the Swiss Federal Institute of Technology
(ETH) in Zurich, the Company is located in Schlieren (Zurich). Cytos
Biotechnology Ltd is listed on the main segment of the SIX Swiss Exchange
Ltd under the symbol CYTN.
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'are intended for', 'are designed to', or
other similar expressions. These forward-looking statements are subject to
a variety of significant uncertainties, including scientific, business,
economic and financial factors, and therefore actual results may differ
significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical
trial results will be predictive for future results, that therapeutic
entities will be the subject of filings for regulatory approval, that any
drug candidates will receive marketing approval from the U.S. Food and Drug
Administration or equivalent regulatory authorities, or that drugs will be
marketed successfully. Against the background of these uncertainties
readers should not rely on forward-looking statements. The Company assumes
no responsibility to update forward-looking statements or adapt them to
future events or developments.
End of Corporate News
---------------------------------------------------------------------
29.03.2012 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Switzerland
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Freiverkehr in Berlin, München, Stuttgart;
Open Market in Frankfurt; SIX
End of News EquityStory AG News-Service
---------------------------------------------------------------------
163087 29.03.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.03.2012 - 17:31 Uhr
Sprache: Deutsch
News-ID 129998
Anzahl Zeichen: 5647
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos invites for the Annual Shareholders' Meeting 2012"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
